--- title: "E Fund's Healthcare ETF (512010) Attracts Over 380 Million in Net Inflows in the Past 4 Days" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/39469953.md" description: "As of 10:39, the CSI 300 Healthcare Index (000913) rose 1.79%. Among the heavyweight stocks, $Jiangsu Hengrui Medicine Co., Ltd.(600276.SH) rose 1.1%, $WuXi AppTec(603259.SH) rose 5.98%, $Mindray Bio-Medical Electronics Co., Ltd.(300760.SZ) rose 0.91%, $United Imaging Healthcare Co., Ltd.(688271.SH) rose 1.27%, $Aier Eye Hospital Group Co., Ltd.(300015.SZ) rose 1.04%, $Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.(600436.SH) rose 0.62%, $Yunnan Baiyao Group Co., Ltd.(000538.SZ) rose 0.95%, $Zhejiang NHU Co., Ltd.(002001.SZ) fell 0.98%, $Huadong Medicine Co., Ltd.(000963.SZ) rose 1.01%, $Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(600196.SH) rose 1.43%..." datetime: "2026-03-24T04:42:50.000Z" locales: - [en](https://longbridge.com/en/topics/39469953.md) - [zh-CN](https://longbridge.com/zh-CN/topics/39469953.md) - [zh-HK](https://longbridge.com/zh-HK/topics/39469953.md) author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)" --- # E Fund's Healthcare ETF (512010) Attracts Over 380 Million in Net Inflows in the Past 4 Days As of 10:39, the CSI 300 Healthcare Index (000913) rose 1.79%. Among the heavyweight stocks, Jiangsu Hengrui Pharmaceuticals Co., Ltd. rose 1.1%, WuXi AppTec rose 5.98%, Mindray Medical International Limited rose 0.91%, United Imaging Healthcare Co., Ltd. rose 1.27%, Aier Eye Hospital Group Co., Ltd. rose 1.04%, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. rose 0.62%, Yunnan Baiyao Group Co., Ltd. rose 0.95%, Zhejiang NHU Co., Ltd. fell 0.98%, Huadong Medicine Co., Ltd. rose 1.01%, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. rose 1.43%. The E Fund Healthcare ETF (512010) is currently the only ETF in the entire market tracking the CSI 300 Healthcare Index, making it a scarce product. The fund continues to attract capital inflows. Data shows that the E Fund Healthcare ETF (512010) has seen net capital inflows for four consecutive days, totaling over 380 million yuan, and over 670 million yuan in the past 20 days. As of the previous trading day, the fund's average daily trading volume in the past month was 438 million yuan, ranking first among its peers, indicating active on-exchange trading and strong liquidity. On the news front, WuXi AppTec announced on the Hong Kong Stock Exchange last night that its total assets have exceeded the 100 billion yuan mark for the first time, officially entering the "100 Billion Asset Club." In 2025, operating revenue was 45.456 billion yuan, a year-on-year increase of 15.84%; net profit attributable to the parent company was 19.195 billion yuan, a year-on-year increase of 105.2%. In terms of regional structure, revenue from the US market was 31.25 billion yuan, a significant year-on-year increase of 34.3%, becoming the primary source of incremental revenue. The cash flow quality is robust: the report shows the company's full-year adjusted operating cash flow reached 16.67 billion yuan, a record high. The company plans to distribute a final dividend of 15.7927 yuan per 10 shares (tax inclusive), totaling approximately 4.712 billion yuan. The company expects overall revenue in 2026 to be between 51.3–53.0 billion yuan, with an expected year-on-year growth of 18%–22% for continuing operations revenue. CITIC Securities stated that the innovative drug sector has shown continued signs of recovery recently, with particularly strong performance in IO (Immuno-Oncology) related pipelines, which is expected to drive a valuation recovery for the innovative drug sector. The current market sees improved cost-effectiveness for allocating to innovative drugs, coupled with gradually clearer Q1 earnings expectations, presenting potential phased allocation opportunities for the sector. It is recommended to focus on innovative pharmaceutical companies with solid clinical progress and internationalization capabilities, paying close attention to core metrics such as pipeline richness, clinical advancement pace, and overseas licensing progress. Related product: The E Fund Healthcare ETF (512010, Off-exchange Link A/C: 001344/007883) packages China's leading pharmaceutical companies in one click, facilitating the allocation to the upward trend and low-valuation investment opportunities in China's pharmaceutical industry. ### Related Stocks - [000913.CN](https://longbridge.com/en/quote/000913.CN.md) - [600436.CN](https://longbridge.com/en/quote/600436.CN.md) - [02196.HK](https://longbridge.com/en/quote/02196.HK.md) - [600196.CN](https://longbridge.com/en/quote/600196.CN.md) - [00656.HK](https://longbridge.com/en/quote/00656.HK.md) - [300015.CN](https://longbridge.com/en/quote/300015.CN.md) - [00388.HK](https://longbridge.com/en/quote/00388.HK.md) - [688271.CN](https://longbridge.com/en/quote/688271.CN.md) - [600276.CN](https://longbridge.com/en/quote/600276.CN.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) - [02359.HK](https://longbridge.com/en/quote/02359.HK.md) - [300760.CN](https://longbridge.com/en/quote/300760.CN.md) - [000538.CN](https://longbridge.com/en/quote/000538.CN.md) - [002001.CN](https://longbridge.com/en/quote/002001.CN.md) - [000963.CN](https://longbridge.com/en/quote/000963.CN.md) - [06030.HK](https://longbridge.com/en/quote/06030.HK.md) - [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md) - [80388.HK](https://longbridge.com/en/quote/80388.HK.md) - [603259.CN](https://longbridge.com/en/quote/603259.CN.md) - [600030.CN](https://longbridge.com/en/quote/600030.CN.md)